NeuroPace Inc. (NPCE) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

NeuroPace Inc. (NPCE)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

11.92

-0.19 (-1.57%)

At close: Jan 14, 2025, 3:59 PM

11.84

-0.67%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	4.74
Market Cap	355.79M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.98
PE Ratio (ttm)	-12.16
Forward PE	n/a
Analyst	Buy

Ask	14.13
Volume	72,261
Avg. Volume (20D)	87,872
Open	12.32
Previous Close	12.11
Day's Range	11.75 - 12.65
52-Week Range	5.45 - 18.15
Beta	undefined

About NPCE

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilitie...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Apr 22, 2021

Employees 184

Stock Exchange NASDAQ

Ticker Symbol NPCE

Website https://www.neuropace.com

Analyst Forecast

According to 5 analyst ratings, the average rating for NPCE stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 17.45% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

NeuroPace Inc. is scheduled to release its earnings on Mar 4, 2025, during market hours.
Analysts project revenue of $21.11M, reflecting a 17.20% YoY growth and earnings per share of -0.24, making a 4.35% increase YoY.

Why Price Moved

2 months ago · Source

+28.15%

Neuropace shares are trading higher after the comp... Unlock content with Pro Subscription

5 months ago · Source

-7.01%

Neuropace shares are trading lower. The company reported Q2 financial results. Wells Fargo lowered its price target on the stock from $20 to $15.

News

2 weeks ago · zacks.com

NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock?

NeuroPace (NPCE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago · zacks.com

Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 31.5% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the posi...

1 month ago · zacks.com

What Makes NeuroPace (NPCE) a New Buy Stock

NeuroPace (NPCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · zacks.com

Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade

The mean of analysts' price targets for NeuroPace (NPCE) points to a 54.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys...

2 months ago · seekingalpha.com

NeuroPace, Inc. (NPCE) Q3 2024 Earnings Call Transcript

NeuroPace, Inc. (NASDAQ:NPCE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Jeremy Feffer – Investor Relations Joel Becker – Chief Executive Officer Rebecca Kuhn ...

2 months ago · zacks.com

NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates

NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.28 per share a year ago.

2 months ago · zacks.com

Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength?

NeuroPace (NPCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r...